Abstract:Objective: To detect the abnormalities of differentiation and expression of membrane hemopoietic cytokine receptors on CD34+ bone marrow cells in patients with myelodysplastic syndromes (MDS). Methods: Forty-five newly diagnosed MDS cases from July 2008 to March 2010 in our hospital and 30 normal controls were enrolled. There were 17 low-risk and 28 high-risk patients. The CD34+ CD38+ and CD34+ CD38- bone marrow cells and the expressions of stem cell factor receptor (SCF-R), erythropoietin receptor (EpoR), granulocyte colony-stimulating factor receptors (G-CSFR) and thrombopoietin receptor (TpoR) on those cells were measured by flow cytometry. Results: The mean percentage of CD34+ in karyocyte of MDS cases in high-risk patients [0.53% (0.10%-1.68%)] was significantly higher than that of control group [0.13% (0.08%-0.32%), P<0.01]. The mean percentages of CD34+ CD38+ cells were significantly lower in low and high-risk groups (86.3%±8.5% and 82.6%±11.1%) than those in control group (92.3%±3.4%). And the percentage of CD34+ CD38- cells was significantly higher in either low-risk or high-risk group (13.7%±8.5% and 17.4%±11.0%) than that in control group (7.7%±3.4%, both P<0.05). In control group, the mean percentage of antigen expression of EpoR was significantly lower in CD34+ CD38+ cells than that in CD34+ CD38- cells (18.7%±18.3% vs 63.6%±20.0%, P<0.01). The expressions of SCF-R, G-CSFR and TpoR were not significantly different between two cell populations. The expressions of EpoR on CD34+ CD38+ cells of low and high-risk MDS groups [9.0% (1.4%-12.7%), 5.2% (1.1%-14.1%)] were significantly lower than those of control group [9.6% (5.1%-30.1%), both P<0.05]. The expressions of G-CSFR on CD34+ CD38+ cells of low and high-risk MDS groups (29.8%±19.1%, 28.7%±21.1%) were significantly lower than those of control group (44.4%±23.4%, both P<0.05). The quantities of EpoR onCD34+ CD38- cells of low and high-risk MDS groups (42.2%±21.9%, 25.7%±15.6%) were significantly lower than those of control group (63.6%±20.0%, both P<0.01). The expressions of TpoR onCD34+ CD38- cells of low and high-risk MDS groups (5.4%±4.7%, 4.1%±4.0%) were significantly lower than those of control group (10.1%±8.3%, both P<0.05). The incidence of cytopenia with low expression rates of hemopoietic cytokine receptors on CD34+ cells was higher than that of MDS with high expression rates. Conclusion: The abnormalities of differentiation and membrane hemopoietic cytokine receptors expression of CD34+ bone marrow cells in MDS are associated with MDS cytopenia and may be useful for the diagnosis of MDS.

Flow cytometric scoring system (FCMSS) assisted diagnosis of myelodysplastic syndromes (MDS) and the biological significance of FCMSS-based immunophenotypes: FCMSS-assisted Diagnosis of MDS

Establishment and Validation of an Updated Diagnostic FCM Scoring System Based on Pooled Immunophenotyping in CD34+ Blasts and Its Clinical Significance for Myelodysplastic Syndromes

[Research Advances in Value of Flow Cytometric Immunophenotyping in Diagnosis and Prognostic Evaluation of Myelodysplastic Syndrome].

Immunophenotyping of myelodysplastic syndromes by flow cytometry and its potential clinical application

Correlation Between Bone Marrow Blasts Counts with Flow Cytometry and Morphological Analysis in Myelodysplastic Syndromes

[Application of Two-parameter Scoring System Based on CD105 and CD117 in MDS Diagnosis].

[Role of Flow Cytometry in the Diagnosis of Chronic Myeloid Leukemia].

Immunophenotypic Features of Myelodysplastic Syndromes by CD45/SSC Gating and Flow Cytometry

[The Value of Flow Cytometry for the Differential Diagnosis Between Refractory Cytopenia with Multiple Dysplasia and Aplastic Anemia].

The Prognostic Value of Early Detection of Minimal Residual Disease As Defined by Flow Cytometry and Gene Mutation Clearance for Myelodysplastic Syndrome Patients after Myeloablative Allogeneic Hematopoietic Stem-Cell Transplantation.

Flow cytometry in the differential diagnosis of myelodysplastic neoplasm with low blasts and cytopenia of other causes

Analysis of the immunophenotype features of bone marrow cells of patients with myelodysplatic syndromes

Evaluation of the Clinical Significance of Immunophenotyping in Myelodysplastic Syndrome.

Value Of Flow Cytometry For Differential Diagnosis Between Refractory Cytopenia With Multilineage Dysplasia And Aplastic Anemia

Qualitative flow cytometric analysis of Malaysian myelodysplastic syndromes (MDS) patients

Myelodysplastic neoplasms dissected into indolent, leukaemic and unfavourable subtypes by computational clustering of haematopoietic stem and progenitor cells

A New Diagnostic Approach for Myelodysplastic Neoplasms Using a Combination of Scores Based on Flow Cytometry and Automated Hematology Sysmex XN Analyzers

Malignant plasmacytes in bone marrow detected by flow cytometry as a predictor for the risk stratification system of multiple myeloma

Immunophenotyping myelodysplastic neoplasms: the role of flow cytometry in the molecular classification era

Multi-color CD34+ progenitor-focused flow cytometric assay in evaluation of myelodysplastic syndromes in patients with post cancer therapy cytopenia

Differentiation and expression of membrane hemopoietic cytokine receptors on CD34+ bone marrow cells in patients with myelodysplastic syndromes